Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 30
2022 54
2023 28
2024 4

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 33597176

101 results

Results by year

Filters applied: . Clear all
Page 1
Monoclonal antibodies for treating COVID-19.
Pallotta AM, Kim C, Gordon SM, Kim A. Pallotta AM, et al. Cleve Clin J Med. 2021 Feb 17. doi: 10.3949/ccjm.88a.ccc074. Online ahead of print. Cleve Clin J Med. 2021. PMID: 33597176 Free article.
Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
Savoldi A, Morra M, De Nardo P, Cattelan AM, Mirandola M, Manfrin V, Scotton P, Giordani MT, Brollo L, Panese S, Lanzafame M, Scroccaro G, Berkell M, Lippi G, Konnova A, Smet M, Malhotra-Kumar S, Kumar-Singh S, Tacconelli E; mAb Working Group. Savoldi A, et al. Eur J Clin Microbiol Infect Dis. 2022 Jul;41(7):1065-1076. doi: 10.1007/s10096-022-04464-x. Epub 2022 Jun 21. Eur J Clin Microbiol Infect Dis. 2022. PMID: 35727429 Free PMC article.
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR, O'Horo JC, Challener DW, Arndt L, Arndt RF, Clune CG, Culbertson TL, Hall ST, Heyliger A, Jackson TA, Kennedy BD, Larsen J, Hanson SN, Sweeten PW, Tulledge-Scheitel SM, Ganesh R. Razonable RR, et al. Mayo Clin Proc. 2022 Sep;97(9):1641-1648. doi: 10.1016/j.mayocp.2022.06.015. Epub 2022 Jun 23. Mayo Clin Proc. 2022. PMID: 36058578 Free PMC article.
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. Kreuzberger N, et al. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. Cochrane Database Syst Rev. 2021. PMID: 34473343 Free PMC article. Review.
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
Hirsch C, Park YS, Piechotta V, Chai KL, Estcourt LJ, Monsef I, Salomon S, Wood EM, So-Osman C, McQuilten Z, Spinner CD, Malin JJ, Stegemann M, Skoetz N, Kreuzberger N. Hirsch C, et al. Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2. Cochrane Database Syst Rev. 2022. PMID: 35713300 Free PMC article. Review.
101 results